Guardant Health has filed a lawsuit against Tempus AI, an AI-based genetic testing company backed by Japanese investment firm SoftBank, for allegedly infringing five patents related to DNA-based cancer testing. The lawsuit, filed in Delaware federal court, claims that Tempus' 'liquid biopsy' cancer tests violate Guardant's patent rights in similar technology. Guardant accuses Tempus of creating 'copycat' liquid biopsy offerings that rely on Guardant’s patented technology, which includes 'cutting-edge innovations' developed 'at great cost through an extensive research and development program.'
Legal Battle in Genetic Testing: Guardant Health vs. Tempus AI #AI #artificialintelligence #Biotechnology #GuardantHealth #llm #machinelearning #TempusAI https://t.co/hGQhetWkL7 https://t.co/bpZVFjkcMP
The company accused Tempus of creating "copycat" liquid biopsy offerings that rely on Guardant’s patented technology including "cutting-edge innovations" developed "at great cost through an extensive research and development program." https://t.co/JDnRBEXCQ6
Guardant Health Sues Tempus for Patent Infringement https://t.co/HUnr9Yfogh
Guardant Health sued AI-based genetic testing company Tempus AI for allegedly infringing five patents related to DNA-based cancer testing, according to a lawsuit. Guardant said that Tempus' ‘liquid biopsy’ cancer tests violate Guardant's patent rights https://t.co/GALG5qLSkT https://t.co/t98RF9IN4p
Guardant Health has sued Tempus AI, an artificial-intelligence-based genetic testing company backed by Japanese investment firm SoftBank, for allegedly infringing five patents related to DNA-based cancer testing, according to a lawsuit made public https://t.co/GALG5qLSkT https://t.co/cUABZnlwTd
Precision oncology company Guardant said in a lawsuit in Delaware federal court that AI-based genetic testing company Tempus' 'liquid biopsy' cancer tests violate Guardant's patent rights in similar technology https://t.co/Reuz47OUkd https://t.co/2eTTLjeCm1
Guardant Health sued Tempus AI, an AI-based genetic testing company backed by Japanese investment firm SoftBank, for allegedly infringing five patents related to DNA-based cancer testing, according to a lawsuit https://t.co/GALG5qLSkT @blakebrittain https://t.co/DxTGCNEqXU